Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial

Simple summaryStereotactic body radiotherapy (SBRT) of 35–36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low–intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There...

詳細記述

書誌詳細

主要な著者:	Valentina Borzillo, Esmeralda Scipilliti, Donato Pezzulla, Marcello Serra, Gianluca Ametrano, Giuseppe Quarto, Sisto Perdonà, Sabrina Rossetti, Sandro Pignata, Anna Crispo, Piergiacomo Di Gennaro, Valentina D’Alesio, Cecilia Arrichiello, Francesca Buonanno, Simona Mercogliano, Antonio Russo, Antonio Tufano, Rossella Di Franco, Paolo Muto
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2023-11-01
シリーズ:	Frontiers in Oncology
主題:	clinical outcome toxicity low-and intermediate-risk radiotherapy prostate cancer stereotactic body radiation
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1270498/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!